Currently, patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B)-mutated melanoma patients are offered immunotherapy (pembrolizumab, nivolumab, or nivolumab and ipilimumab combination) or BRAF and MEK (Mitogen-Activated Protein Kinase Kinase 1, MAP2K1) inhibitors combination (BRAFi/MEKi) as a first line therapy [1,2,3,4]. Here, BRAF is linked to melanoma.